Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob S Aday

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
ACS Pharmacology & Translational Science|April 16, 2021
Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug EffectsJacob S Aday, Alan K Davis, Cayla M Mitzkovitz, et al.
Frontiers in Psychiatry|March 8, 2024
Psychedelic substitution: altered substance use patterns following psychedelic use in a global surveyNicolas G Glynos, Jacob S Aday, Daniel Kruger, et al.
Psychopharmacology|April 1, 2022
Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trialsJacob S Aday, Boris D Heifets, Steven D Pratscher, et al.
Brain and Behavior|November 14, 2025
The Relationship Between Psychedelic Use and Positive Adult Development in Emerging Adulthood: An Integrative ReviewJake Payne, Oliver Robinson, Kevin St Arnaud, et al.
Consciousness and Cognition|July 11, 2020
Meditation alters representations of peripersonal space: Evidence from auditory evoked potentialsViet Han H Nguyen, Shannon B Palmer, Jacob S Aday, et al.
Psychedelic Medicine (New Rochelle, N.Y.)|March 6, 2025
Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic IndustryJacob S Aday, Brian S Barnett, Dan Grossman, et al.
British Journal of Pain|February 13, 2025
Psychedelics and chronic pain: self-reported outcomes on changed substance use patterns and health following naturalistic psychedelic useNicolas G Glynos, Anne Baker, Jacob S Aday, et al.
Journal of Psychopharmacology (Oxford, England)|December 13, 2021
Debunking the myth of 'Blue Mondays': No evidence of affect drop after taking clinical MDMABen Sessa, Jacob S Aday, Steve O'Brien, et al.
Psychopharmacology|May 23, 2024
Psychedelic-assisted psychotherapy: where is the psychotherapy research?Jacob S Aday, David Horton, Gisele Fernandes-Osterhold, et al.
Journal of Psychoactive Drugs|September 19, 2024
Going Underground: Demographics, Services, and Best Practices Endorsed by Practitioners Providing Support for Naturalistic Psychedelic UseNicolas G Glynos, Anne Baker, Jacob S Aday, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
ACS Pharmacology & Translational Science|April 16, 2021
Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug EffectsJacob S Aday, Alan K Davis, Cayla M Mitzkovitz, et al.
Frontiers in Psychiatry|March 8, 2024
Psychedelic substitution: altered substance use patterns following psychedelic use in a global surveyNicolas G Glynos, Jacob S Aday, Daniel Kruger, et al.
Psychopharmacology|April 1, 2022
Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trialsJacob S Aday, Boris D Heifets, Steven D Pratscher, et al.
Brain and Behavior|November 14, 2025
The Relationship Between Psychedelic Use and Positive Adult Development in Emerging Adulthood: An Integrative ReviewJake Payne, Oliver Robinson, Kevin St Arnaud, et al.
Consciousness and Cognition|July 11, 2020
Meditation alters representations of peripersonal space: Evidence from auditory evoked potentialsViet Han H Nguyen, Shannon B Palmer, Jacob S Aday, et al.
Psychedelic Medicine (New Rochelle, N.Y.)|March 6, 2025
Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic IndustryJacob S Aday, Brian S Barnett, Dan Grossman, et al.
British Journal of Pain|February 13, 2025
Psychedelics and chronic pain: self-reported outcomes on changed substance use patterns and health following naturalistic psychedelic useNicolas G Glynos, Anne Baker, Jacob S Aday, et al.
Journal of Psychopharmacology (Oxford, England)|December 13, 2021
Debunking the myth of 'Blue Mondays': No evidence of affect drop after taking clinical MDMABen Sessa, Jacob S Aday, Steve O'Brien, et al.
Psychopharmacology|May 23, 2024
Psychedelic-assisted psychotherapy: where is the psychotherapy research?Jacob S Aday, David Horton, Gisele Fernandes-Osterhold, et al.
Journal of Psychoactive Drugs|September 19, 2024
Going Underground: Demographics, Services, and Best Practices Endorsed by Practitioners Providing Support for Naturalistic Psychedelic UseNicolas G Glynos, Anne Baker, Jacob S Aday, et al.
Pageof 4